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ttp://dx.doi.org/10.1016/j.ajpath.2013.03.012Tumor cells accumulate high level of reactive oxygen species (ROS) because they are metabolically more
active than normal cells. Elevated ROS levels increase tumorigenecity but also render cancer cells more
vulnerable to oxidative stress than normal cells. The oncogenic transcription factor Forkhead Box M1
(FOXM1), which is overexpressed in a wide range of human cancers, was reported to protect cancer cells
from the adverse effects of oxidative stress by up regulating the expression of scavenger enzymes. We
therefore hypothesized that the combination of FOXM1 ablation and ROS inducers could selectively
eradicate cancer cells. We show that RNA interferenceemediated knockdown of FOXM1 further elevates
intracellular ROS levels and increases sensitivity of cancer cells to ROS-mediated cell death after
treatment with ROS inducers. We also demonstrate that the combination of ROS inducers with FOXM1/
proteasome inhibitors induces robust apoptosis in different human cancer cells. In addition, we show
evidence that FOXM1/proteasome inhibitor bortezomib in combination with the ROS inducer b-phe-
nylethyl isothiocyanate efﬁciently inhibits the growth of breast tumor xenografts in nude mice. We
conclude that the combination of ROS inducers and FOXM1 inhibitors could be used as a therapeutic
strategy to selectively eliminate cancer cells. (Am J Pathol 2013, 183: 257e265; http://dx.doi.org/
10.1016/j.ajpath.2013.03.012)Supported by NIH grant 1RO1CA1294414 (A.L.G.).Reactive oxygen species (ROS) can be generated as by-
products of oxidative phosphorylation and also after envi-
ronmental stress by exogenous sources, such as ionizing
radiation, UV light, and redox chemicals.1 ROS are highly
reactive and are usually considered to be harmful because
they can damage proteins, lipids, and DNA.1,2 Consequently,
cells to protect themselves from the adverse effects of ROS
have developed a complex antioxidant defense system.1
However, ROS have also been recognized to play an
important role in many different physiologic processes, such
as proliferation, cell signaling, metabolism, aging, cell death,
and cancer.2 Oxidative stress occurs when the balance
between ROS production and detoxiﬁcation is compromised
and the generation of ROS overcomes the antioxidant
defense system of the cell.1,3
In cancer treatment it is a daunting challenge to selec-
tively eradicate cancer cells but spare normal cells. An
alternative approach to achieve this goal is to take advantagestigative Pathology.
.of the biochemical alterations in cancer cells instead of
targeting one speciﬁc oncogene.4 One common biochemical
alteration in cancer cells is that they accumulate higher level
of ROS due to their increased metabolic activity.5 Elevated
ROS levels accelerate protumorigenic signaling pathways
and increase mutation rates, thereby enhancing tumorigen-
esis. However, the high levels of ROS in cancer cells also
render them more prone to oxidative stress and more
dependent on their antioxidant system.4 Studies have re-
ported that such an abnormal increase in ROS could be
exploited to preferentially kill cancer cells by inducing
oxidative stress.4,6
Mammalian, oncogenic transcription factor Forkhead Box
M1 (FOXM1) has a well-deﬁned role in cell proliferation and
cell cycle progression.7 Expression of FOXM1 is excluded in
resting or differentiated cells, but its level is highly elevated
Halasi et alin proliferating and malignant cells, and also in different
human cancers.7 In recent years FOXM1 has been impli-
cated in diverse cellular processes,8 including oxidative
stress.9 FOXM1 was identiﬁed as a pivotal regulator of
oncogene-induced ROS in cycling cells. FOXM1, by di-
rectly regulating the expression of scavenger enzymes,
reduces intracellular ROS levels, thus protecting tumor
cells from oxidative stress and allowing their proliferation.9
Because FOXM1 is so abundantly expressed in human
cancers, the authors of the study postulated that cancer cells
become accustomed to elevated ROS levels by the over-
expression of FOXM1.9
Recently, we reported that repression of FOXM1 sensi-
tizes human cancer cells to DNA damage.10 In this study,
we examined the combinatorial effect of FOXM1 suppres-
sion in conjunction with oxidative stress on cell death
in vitro and xenograft tumor growth in vivo. We found
that RNA interference (RNAi)emediated knockdown of
FOXM1 leads to the elevation of intracellular ROS levels
and increases sensitivity to ROS-mediated cell death after
treatment with ROS inducers, including b-phenylethyl iso-
thiocyanate (PEITC) and 2-methoxyestradiaol (2-ME) in
different human cancer cells. Moreover, we found that the
combination of ROS inducers with proteasome inhibitors
that target FOXM1 induces robust apoptosis and efﬁ-
ciently inhibits the growth of breast tumor xenografts in
nude mice.
Materials and Methods
Cell Culture and Chemical Compounds
The MIA PaCa-2 pancreatic (ATCC, Manassas, VA) and the
HepG2 liver (ATCC) human cancer cell lines were grown in
Dulbecco’s modiﬁed Eagle’s medium (DMEM; Invitrogen,
Carlsbad, CA). The MDA-MB-231 (ATCC) breast human
cancer cell line was grown in RPMI medium (Invitrogen).
The media were supplemented with 10% fetal bovine serum
(FBS; Atlanta Biologicals, Atlanta, GA) and 1% penicillin-
streptomycin (Gibco, Grand Island, NY). BJ primary human
foreskin ﬁbroblasts (ATCC) and BJ oncogenic cells
(Dr. William Hahn, Harvard Medical School, Boston, MA)
were grown in knockout DMEM and medium 199 (Invi-
trogen) supplemented with 15% FBS (Atlanta Biologicals),
2mmol/L L-glutamine (Gibco), and 1%penicillin-streptomycin
(Gibco). All of the cells were maintained at 37C in 5% CO2.
Stable cell lines using theATCC-obtained parental cells were
generated by transduction of control and FOXM1 shRNA
lentiviral particles (Sigma, St. Louis, MO) followed by
selection with puromycin (Sigma). PEITC (Sigma), 2-ME
(Sigma), thiostrepton (Sigma), and bortezomib (Velcade;
Millenium Pharmaceuticals, St. Louis, MO) were dissolved
in dimethyl sulfoxide (DMSO; Fisher Scientiﬁc, Chicago,
IL), H2O2 (Fisher Scientiﬁc) in culture media, N-acetyl-L-
cysteine (NAC) (Sigma), and glutathione (Sigma) in deion-
ized water.258Immunoblot Analysis
Treated cells and tumor tissues were harvested and lysed by
using IP buffer [20 mmol/L HEPES, 1% Triton X-100,
150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA,
100 mmol/L NaF, 10 mmol/L Na4P2O7, 1 mmol/L sodium
orthovanadate, and 0.2 mmol/L phenylmethylsulfonyl
ﬂuoride supplemented with protease inhibitor tablet (Roche
Applied Sciences, Indianapolis, IN)]. Protein concentration
was determined by the Bio-Rad protein assay reagent (Bio-
Rad, Hercules, CA). Isolated proteins were separated on
SDS-PAGE and transferred to polyvinylidene diﬂuoride
membrane (PVDF; Millipore, Billerica, MA). Immuno-
blotting was performed with antibodies speciﬁc for FOXM1
(the rabbit polyclonal antibody against FOXM1 was
described previously11), cleaved caspase-3 (Cell Signaling,
Danvers, MA), poly (ADP-ribose) polymerase (PARP) 1/2
(Santa Cruz Biotechnology, Santa Cruz, CA), catalase
(Abcam, Cambridge, MA), MnSOD (Stressgen, San Diego,
CA), and b-actin (Sigma).
Transfection and siRNA
Control (5'-AACAGUCGCGUUUGCGACUGGUU-3') siRNA
and siRNA speciﬁc to FOXM1 (5'-GGACCACUUUCCCU-
ACUUUUU-3') were synthesized by Sigma. Fifty nanomolar
siRNA duplexes were transfected into cells using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s
recommendation. Cells were treated as indicated 48 or
72 hours after transfection.
Adenoviral Infection
Human cancer cells were infected with adenoviral particles
(Gene Transfer Vector Core, University of Iowa, Ames, IA)
at MOI 100 in FBS free media for 1 hour. Then the FBS
concentration was brought up to 10% and additional media
was added. Forty-eight hours after infection the cells were
treated as indicated.
Flow Cytometry
Propidium Iodide Staining
Cells were treated as indicated and harvested by trypsiniza-
tion. Then cellswerewashed in PBS andﬁxed in ice-cold 95%
ethanol. After ﬁxation, cells were stained with 50 mg/mL of
propidium iodide (Invitrogen) in PBS/RNase A/Triton X-100
for 30 minutes at room temperature and analyzed by ﬂow
cytometry.
Annexin V-PE/7-AAD Staining
Cells were stained using the Annexin Vephycoerythrin
(PE) apoptosis detection kit (Enzo Life Sciences, Farm-
ingdale, NY). Harvested cells were washed in PBS and
resuspended in binding buffer, and 5 mL of Annexin VePE
and 5 mL of 7-AAD were added. After 15 minute incubationajp.amjpathol.org - The American Journal of Pathology
Figure 1 Suppression of FOXM1 by RNAi sensitizes human cancer cells to H2O2-induced oxidative stress. A: Treatment strategy. FOXM1 reduces intracellular
ROS levels by inducing the expression of ROS scavengers. Co-treatment with ROS inducers and FOXM1 inhibitors elevates the levels of ROS, leading to cell
death. B: Breast cancer cells MDA-MB-231 were transfected with control and FOXM1 siRNA for 72 hours, then treated with 300 mmol/L H2O2 and 10 mmol/L
H2DCF-DA dye for 30 minutes. Intracellular ROS production was determined by ﬂow cytometry. Graph shows quantiﬁcation as fold of ROS induction compared
with control cells, means  SD of a representative triplicate experiment. C: MIA PaCa-2 vector control and FOXM1 knockdown pancreatic cancer cells were
treated with the indicated concentrations of H2O2. Twenty-four hours after treatment, cells were harvested and immunoblotting was performed with antibodies
against cleaved caspase-3. b-Actin was used as the loading control. D: MDA-MB-231 vector control and FOXM1 knockdown breast cancer cells were treated with
H2O2 as indicated. Twenty-four hours after treatment, cells were harvested and immunoblotting was performed for cleaved caspase-3 and b-actin as the
loading control.
FOXM1 and Oxidative Stressin the dark at room temperature, the samples were analyzed
by ﬂow cytometry.
ROS Measurement
Cells were incubated with 10 mmol/L H2DCF-DA dye
(Molecular Probes) for 30 minutes. Then cells were washed
with PBS, trypsinized, and analyzed for intracellular ROS
production by ﬂow cytometry.
CI Measurement by the Chou-Talalay Median-Effect
Method
Serial dilutions of each drug were made and combined from
the lowest to the highest concentration, while measuring
the cell fraction affected. In our experiments, IC20 to IC95
(fractional effect 0.2 to 0.95) values (drug concentrations
needed to cause 20% to 95% reduction in cell viability) were
used for measurements. The percentage of viable cells was
assessed by the standardMTT assay. Combination index (CI)
values were calculated with the formula described in the
article by Chou.12 CI values of <1 indicate synergy, a value
of 1 additive effects, and values of >1 antagonism.The American Journal of Pathology - ajp.amjpathol.orgAnchorage-Dependent Growth Assay (Colony-Forming
Assay)
A total of 1  105 cells were plated on 100 mm dishes in
duplicate and were treated as indicated for 24 hours.
Colonies were allowed to form for 10 days, and then cells
were stained with crystal violet. Quantiﬁcation of colonies
was performed with ImageJ (NIH).Xenograft Animal Experiment
Four-week-old, male, athymic, nude mice were purchased
from Taconic (Petersburgh, NY). Bilaterally, 2  106 MDA-
MB-231 cells per site in a 100 mL mixture of 70% Matrigel
(BD Biosciences, San Jose, CA) and 30% PBS were injected
s.c. in the ﬂank region. After tumors became palpable, tumor
size was measured once a week using a Vernier caliper, and
tumor volume was calculated with the following formula:
(length  width  height)/2. When tumors reached 70 mm3
in size, mice were divided into the following treatment
groups: control (untreated), PEITC (25 mg/kg), bortezomib
(0.4 mg/kg), and the combination of PEITC and bortezomib.259
Figure 2 Suppression of FOXM1 by RNAi further elevates ROS levels and increases cell death after treatment with known ROS inducers. A: MIA PaCa-2
pancreatic and MDA-MB-231 breast cancer cells were transfected with control and FOXM1 siRNA for 72 hours, then treated with 5 mmol/L PEITC for
3 hours. After treatment, cells were incubated with 10 mmol/L H2DCF-DA dye for 30 minutes and analyzed for intracellular ROS production by ﬂow
cytometry. Graph shows quantiﬁcation as fold of ROS induction compared with control cells, means  SEM of two (left) or three (right) independent
experiments, respectively. B: MIA PaCa-2 pancreatic and MDA-MB-231 breast vector control and FOXM1 knockdown cancer cells were treated with PEITC
as indicated. Three hours after treatment, cells were incubated with 10 mmol/L H2DCF-DA dye for 30 minutes, and intracellular ROS production was
measured by ﬂow cytometry. Graph shows quantiﬁcation as fold of ROS induction compared with control cells, means  SEM of four (left) or two (right)
independent experiments, respectively. C: MIA PaCa-2 vector control and FOXM1 knockdown pancreatic cancer cells were treated with the indicated
concentrations of PEITC. Twenty-four hours after treatment, cell lysates were immunoblotted for FOXM1, cleaved caspase-3, and b-actin as the loading
control. D: Degree of cell death was assessed by ﬂow cytometry after propidium iodide staining in MIA PaCa-2 pancreatic vector control and FOXM1
knockdown cancer cells 6 hours after PEITC treatment. Graph shows quantiﬁcation as fold of cell death induction compared with control cells, means 
SEM of two independent experiments. E: MDA-MB-231 vector control and FOXM1 knockdown breast cancer cells were treated with PEITC as indicated.
Immunoblot analysis was performed for FOXM1, cleaved caspase-3, and b-actin as the loading control, 24 hours after treatment. F: MDA-MB-231 breast
vector control and FOXM1 knockdown cancer cells were treated with 7 mmol/L PEITC for 24 hours. Cell death was determined by PE Annexin V/7-AAD
assay. G: Graph shows quantiﬁcation as fold of cell death induction compared with control cells, means  SEM of three independent experiments
under the same conditions as in F. H: Pancreatic MIA PaCa-2 vector control and FOXM1 knockdown cancer cells were treated with the indicated
concentrations of 2-ME. Twenty-four hours after treatment, cell lysates were immunoblotted for FOXM1, cleaved caspase-3, and b-actin as the loading
control. I: Breast MDA-MB-231 vector control and FOXM1 knockdown cancer cells were treated with 2-ME as indicated. Immunoblot analysis was
performed for FOXM1, cleaved caspase-3, and b-actin as the loading control 24 hours after treatment.
Halasi et alPEITC was dissolved in a solvent that consisted of ethanol,
Cremophor-EL (Sigma), and PBS in a ratio of 1:1:8 and
bortezomib in saline. All drugs were administered i.p. 4 to 5
times per week up to 25 injections. At the completion of the
study, mice were sacriﬁced by CO2 inhalation followed by
cervical dislocation, and tumors were excised. All of the
procedures that involved animals were in accordance with
and approved by the Animal Care and Use Committee of the
University of Illinois at Chicago.260Results
Knockdown of FOXM1 Sensitizes Human Cancer Cells to
Oxidative StresseInduced Cell Death
In general, cancer cells exhibit higher level of ROS as
a result of their increased metabolic activity.5 It has been
suggested that malignant cells might adapt to elevated ROS
levels by overexpressing FOXM1. FOXM1 down regulatesajp.amjpathol.org - The American Journal of Pathology
Figure 3 PEITC induces ROS-dependent apoptosis in FOXM1 knockdown cells. A: MIA PaCa-2 pancreatic and MDA-MB-231 breast FOXM1 knockdown cancer cells
were preincubatedwith ROS inhibitor NAC for 2 hours, after which theywere treatedwith PEITC as indicated for 3 hours. Intracellular ROS productionwas determined
byﬂow cytometry after incubating the cells with 10mmol/L H2DCF-DA dye for 30minutes. Graph shows quantiﬁcation as fold of ROS induction comparedwith control
cells, means SEM of two independent experiments. B: MIA PaCa-2 pancreatic FOXM1 knockdown cancer cells were preincubated with ROS inhibitor NAC for 2 hours
then treated with the indicated concentrations of PEITC. Twenty-four hours after treatment, cell lysates were immunoblotted for PARP, cleaved caspase-3, and
b-actin as the loading control. C: MDA-MB-231 breast FOXM1 knockdown cancer cells were preincubated with ROS inhibitors NAC and glutathione for 3 hours then
treatedwith PEITC as indicated. Twenty-four hours after treatment, cell lysateswere immunoblotted for PARP, cleaved caspase-3, andb-actin as the loading control.
D: MDA-MB-231 breast FOXM1 knockdown cancer cells were infected with MnSOD or catalase adenoviral particles for 48 hours or were preincubated with NAC for
1 hour. Then the vector control and FOXM1 knockdown breast cancer cells were treated with PEITC as indicated for 10 hours. Immunoblotting was performed with
antibodies speciﬁc for anti-catalase, MnSOD, cleaved caspase-3, and PARP.b-Actinwas used as the loading control. E: MDA-MB-231 breast FOXM1 knockdown cancer
cells were preincubated with NAC for 2 hours and then treated with 7 mmol/L PEITC for 24 hours. Cell death was determined by PE Annexin V/7-AAD assay. F: Graph
showsquantiﬁcationas fold of cell death inductioncomparedwith control cells,means SDofa representative duplicate experimentunder the sameconditionsas inE.
FOXM1 and Oxidative StressROS levels via direct activation of the transcription of anti-
oxidant enzymes, thus protecting tumor cells from oxidative
stress9 (Figure 1A). Consequently, suppression of FOXM1
would counteract its inhibitory action on ROS production,
and the combination ofROS inducerswith FOXM1 inhibition
could elevate ROS beyond threshold level, leading to the
death of malignant cells (Figure 1A). Because normal cells
express very low level of FOXM1 and are not as dependent on
their antioxidant system as tumor cells, this treatment strategy
would primarily target cancer cells and spare normal cells.
In agreement with earlier studies,9 we also observed that
transient depletion of FOXM1 results in higher ROS levels
compared with control cells as assessed by ﬂow cytometry
after incubation with dichlorodihydroﬂuorescein diacetate
(H2DCF-DA) dye (Figure 1B). We also found that exposureThe American Journal of Pathology - ajp.amjpathol.orgto H2O2 notably increased intracellular ROS levels in
FOXM1-deﬁcient breast cancer cells relative to treated
control cells (Figure 1B). In addition, cell death was detected
by immunoblotting for cleaved caspase-3, a marker of
apoptosis (Figure 1, C and D) after treatment with different
concentrations of H2O2 in human cancer cells of different
origin harboring stable knockdown of FOXM1. We found
that knockdown of FOXM1 increased sensitivity of pancre-
atic and breast cancer cells to H2O2-mediated apoptosis.
These data suggest that in FOXM1-depleted human cancer
cells elevated ROS levels associate with increased cell death
after exposure to oxidative stress.
Next, we examined whether FOXM1 suppression sensi-
tizes cancer cells to oxidative stress induced by other types
of ROS inducers. To this end, we treated transient and stable261
Figure 4 Combination of FOXM1/proteasome inhibitors and ROS inducers sensitizes human cancer cells to programmed cell death. A: Primary BJ
ﬁbroblasts and BJ oncogenic cells were treated with thiostrepton (thio) or bortezomib (bor) in combination with PEITC or 2-ME for 24 hours. Immu-
noblotting was performed with antibodies speciﬁc for anti-PARP and cleaved caspase-3. b-Actin was used as the loading control. B: MDA-MB-231 breast
cancer cell line was treated with PEITC in combination with thio or bor as indicated for 24 hours. Cell lysates were analyzed by immunoblotting with
antibodies speciﬁc for anti-FOXM1, cleaved caspase-3, and b-actin as the loading control. C: Pancreatic cancer cell line MIA PaCa-2 was treated with the
indicated concentrations of PEITC, thio, and bor alone or in combination. Twenty-four hours after treatment, cell lysates were analyzed by immuno-
blotting with anti-FOXM1, cleaved caspase-3, and b-actin antibodies. D: Cell death was assessed by ﬂow cytometry after propidium iodide staining in MIA
PaCa-2 pancreatic cancer cells 24 hours after the indicated treatments. Graph shows quantiﬁcation as fold of cell death induction compared with control
cells, means  SEM of two independent experiments. E: HepG2 liver cancer cells were treated with PEITC and thio alone or in combination as indicated
for 24 hours. Immunoblot analysis was performed with anti-FOXM1, cleaved caspase-3, and b-actin antibodies. F: HepG2 liver cancer cells were treated
with PEITC and bor alone or in combination with the indicated concentrations for 24 hours. Immunoblotting was performed with antibodies speciﬁc for
anti-FOXM1, cleaved caspase-3, and b-actin as the loading control.
Halasi et alFOXM1 knockdown pancreatic and breast cancer cells along
with their corresponding control counterparts with PEITC.
PEITC is a natural compound found in cruciferous vegetables
with chemopreventive activity that has been found to increase
ROS generation13 and to induce apoptosis in cancer cell
lines.14,15 It is currently in clinical trials. We measured ROS
levels byﬂow cytometry and found that treatmentwith PEITC
also generated more ROS in FOXM1 knockdown cells
compared with treated control cells (Figure 2, A and B). We
also observed that cells with FOXM1 knockdown were more
susceptible to apoptosis after PEITC treatment as detected by
immunoblotting for cleaved caspase-3 (Figure 2, C andE) and
by ﬂow cytometry after propidium iodide (Figure 2D) or
Annexin V staining (Figure 2, F and G). To conﬁrm these
effects, the pancreatic and breast cancer cells with stable
FOXM1 knockdown were treated with 2-ME, another ROS
inducer,16 and also in clinical trials. 2-ME treatment also
elevated ROS levels in FOXM1 knockdown cells compared
with their treated control counterparts (data not shown).
In addition, Western blot analysis of cleaved caspase-3
demonstrated that FOXM1 knockdown pancreatic and
breast cancer cells were more sensitive to 2-MEeinduced
apoptosis (Figure 2, H and I). Altogether, these data suggest
that suppression of FOXM1 further sensitizes cancer cells to262oxidative stressemediated apoptosis induced by different
types of ROS inducers.
PEITC-Induced Apoptosis in FOXM1 Knockdown Cells Is
ROS Dependent
To verify that PEITC-induced cell death is ROS mediated in
the cell lines tested, MIA PaCa-2 pancreatic and MDA-MB-
231 breast FOXM1 knockdown cancer cells were treated
with different concentrations of PEITC in the presence or
absence of various antioxidants, including NAC, gluta-
thione, catalase, and MnSOD. We determined ROS levels
by ﬂow cytometry and found that PEITC treatment elevated
ROS levels and that the antioxidants NAC (Figure 3A),
catalase, and MnSOD (data not shown) efﬁciently prevented
PEITC-induced ROS accumulation. Next, apoptosis was
determined by immunoblotting for cleaved caspase-3 or
PARP (Figure 3, BeD) and by ﬂow cytometry after
Annexin V staining (Figure 3, E and F). We found that NAC
and glutathione completely diminished cell death (Figure 3,
B and C), whereas overexpression of FOXM1 direct tran-
scriptional targets catalase and MnSOD9 partially protected
against cell death (Figure 3D) in the PEITC-treated FOXM1
knockdown cells, suggesting that ROS is indeed involved inajp.amjpathol.org - The American Journal of Pathology
Figure 5 Combination of FOXM1/proteasome
inhibitors and ROS inducer PEITC synergistically
inhibits cell viability and long-term colony
formation. A: Combination of PEITC with bortezo-
mib (bor) or thiostrepton (thio), respectively, is
synergistic in inhibiting proliferation of cancer
cells. The CI chart for the PEITC/bor or PEITC/thio
drug combinations was plotted with CI on the
y axis and fractional effect on the x axis.
Percentage inhibition of viability was determined
after treatment with a single agent or the PEITC/
bor and PEITC/thio combination, respectively. The
CI values of the agents are plotted for MIA PaCa-2
pancreatic and MDA-MB-231 breast cancer cells. B:
A total of 1  105 MIA PaCa-2 human pancreatic
cancer cells were plated and treated as indicated
for 24 hours. Ten days after treatment, cells were
stained with crystal violet and representative
plates are shown. C: Graph shows the quantiﬁca-
tion means  SD of duplicate experiments. D:
A total of 1  105 MDA-MB-231 human breast
cancer cells were plated and treated as indicated
for 24 hours. Ten days after treatment, cells were
stained with crystal violet and representative
plates are shown. E: Graph shows the quantiﬁca-
tion means  SD of duplicate experiments.
FOXM1 and Oxidative StressPEITC-induced cell death in pancreatic and breast cancer
cells after FOXM1 suppression.
Treatment With Proteasome Inhibitors Sensitizes
Human Cancer Cells to Apoptosis Induced by Oxidative
Stress
We previously identiﬁed the thiazole antibiotics thiostrepton
and Siomycin A as potent FOXM1 inhibitors17-20 and found
that they also exhibit proteasome inhibitory activity.21 More
importantly, we found that bona ﬁde proteasome inhibitors
such as bortezomib (Velcade) and MG132 also inhibit
FOXM1.21 To test FOXM1/proteasome inhibitors together
with ROS inducers, we examined whether this combinato-
rial treatment has speciﬁcity toward transformed cells
compared with normal cells. We observed that treatment of
isogenic human foreskin ﬁbroblast cells with thiostrepton or
bortezomib in combination with PEITC or 2-ME induced
apoptosis in the Ras-transformed oncogenic cells but not in
the primary ﬁbroblasts as detected by the cleavage of
caspase-3 and PARP (Figure 4A). This observation suggests
that combination of FOXM1/proteasome inhibitors and
ROS inducers might speciﬁcally kill cancer cells and spare
normal ones, thus reducing their potential toxicity in the
treatment of human cancer.
Next, we assessed the sensitivity of breast, pancreatic, and
liver cancer cells to cell death induced by the combination of
subapoptotic concentrations of proteasome inhibitors andThe American Journal of Pathology - ajp.amjpathol.orgROS inducers. To this end,MDA-MB-231 breast,MIAPaCa-2
pancreatic, and HepG2 liver cancer cell lines were treated
with the combination of PEITC and thiostrepton or bortezo-
mib (Figure 4, BeF), respectively.We found that thiostrepton
and bortezomib in conjunction with PEITC decreased
FOXM1 expression (Figure 4, B, C, E, F) and induced cell
death compared with single drug treatment in these particular
cancer cells as depicted by cleaved caspase-3 (Figure 4, B, C,
E, F) and by ﬂow cytometry after propidium iodide staining
(Figure 4D).
In addition, the synergistic nature of the interaction
between PEITC and bortezomib or thiostrepton was quan-
titatively validated after measurement of cell viability after
single and combination drug treatments using the Chou-
Talalay median-effect equation method. CI values <1
indicate a synergistic antiproliferative effect. The CI values
for the combined treatments with PEITC/bortezomib in MIA
PaCa-2 pancreatic and MDA-MB-231 breast (Figure 5A)
cancer cells range from 0.25 to 0.80 for fractional effect
corresponding to 0.95 to 0.20, suggesting a strong synergistic
effect. Similarly, the CI values for the combined treatments
with PEITC/thiostrepton in MIA PaCa-2 cancer cells range
from 0.60 to 0.80 for fractional effect, corresponding to 0.95
to 0.20 (Figure 5A).
Because the combination of FOXM1/proteasome inhibi-
tors and ROS inducers efﬁciently increased cell death, their
combinatorial effect on long-term survival was also tested by
performing clonogenic assay. The colony-forming capacity263
Figure 6 Combination of FOXM1/proteasome
inhibitor bortezomib (bor) and ROS inducer PEITC
inhibits tumor growth in vivo. A: MDA-MB-231
breast cancer cells (2  106) were injected s.c.
into the ﬂank region on both sides of 4eweek-old,
male, nude mice. After tumors became palpable
their size was recorded weekly by caliper measure-
ment. Animals were dosed with the indicated
concentrations of the drugs 4 to 5 times per week up
to 25 injections in total. Graph demonstrates
differences in rates of tumor growth during the
study period. B: Graph shows the change in weight
of the animals during the treatment period. C: Graph
shows differences in weight of the excised tumors.
D: Representative image of the excised tumors is
shown. E: Homogenized tumor samples were used
for immunoblotting to determine the level of FOXM1
and cleaved caspase-3. b-Actin was used as the
loading control.
Halasi et alof pancreatic and breast cancer cells was determined after
treatment with PEITC in combination with thiostrepton or
bortezomib (Figure 5, BeE). We observed that the combi-
nation of PEITC with FOXM1/proteasome inhibitors
considerably reduced the number of colonies relative to
control and single drug treatment. Taken together, these data
suggest that combination of oxidative stress and FOXM1
suppression could result in an effective strategy to kill cancer
cells.
Combination of Bortezomib and PEITC Inhibits
Xenograft Tumor Growth
The potential anticancer activity of FOXM1/proteasome
inhibitors in combination with ROS inducers was also evalu-
ated in nude mice bearing breast tumor xenografts. Male
athymic nude mice were injected s.c. with MDA-MB-231
human breast cancer cells in the ﬂank region bilaterally to
establish xenograft tumors.After tumors becamepalpable, their
sizewasmeasured by caliper and the animals were randomized
into the following treatment groups: (1) untreated, (2) PEITC
(25 mg/kg), (3) bortezomib (0.4 mg/kg), and (4) PEITC and
bortezomib. Animals were injected i.p. with the drugs 4 to
5 times per week. Tumor size was recorded weekly. Upon
completion of the study, mice were sacriﬁced by CO2 inhala-
tion and cervical dislocation, and their tumors were excised.
The mean of tumor volume was plotted against time in
weeks to monitor growth of the breast tumor xenografts.
During the study period, the combination of PEITC and
bortezomib signiﬁcantly inhibited the growth of MDA-
MB-231 human breast tumor xenografts compared with
untreated and single drug treatment (Figure 6A). We also
found that the doses used for this study did not induce any
undue toxic effects. As demonstrated, only the animals
injected with the combination of PEITC and bortezomib264lost weight (Figure 6B). However, any likely toxic effect
was not lethal, and the weight loss reached a maximum of
approximately 10%. The excised tumors were weighed.
The tumors treated with the combination of PEITC and
bortezomib weighed signiﬁcantly less (Figure 6C) and
were much smaller (Figure 6D) relative to untreated and
single drug treated tumors. Harvested tumors were also
examined for FOXM1 level by immunoblotting. FOXM1
expression was strongly suppressed in tumor samples
treated with the combination of the drugs compared with
untreated samples (Figure 6E). Furthermore, Western blot
analysis for cleaved caspase-3 demonstrated that tumors
were more sensitive to the combination of PEITC with
bortezomib (Figure 6E), suggesting that the repression of
tumor growth by the combination treatment might be
a result of the induction of cell death in the tumor cells.
Collectively, these data suggest that proteasome inhibitors
in combination with ROS inducers could suppress tumor
growth in human cancer xenograft models, implying that
they could have potential anticancer activities in patients
as well.
Discussion
The aim of this study was to explore the potential of the
combination of oxidative stress with FOXM1 suppression
in vitro and in vivo. We showed evidence that after treatment
with ROS inducers FOXM1 suppression by RNAi further
elevates intracellular ROS levels (Figure 1B and Figure 2, A
and B) and sensitizes human cancer cells of different origin to
apoptosis (Figure 1, C and D and Figure 2, CeI) that is ROS
dependent (Figure 3, BeF). Moreover, overexpression of the
FOXM1 target scavenger MnSOD partially reversed this
effect (Figure 3D). These data conﬁrm that FOXM1 exerts its
antioxidant activity in part via the activation of MnSOD. Weajp.amjpathol.org - The American Journal of Pathology
FOXM1 and Oxidative Stressalso found that treatment with FOXM1/proteasome inhibitors
along with ROS inducers greatly increases the sensitivity of
cancer cells to cell death (Figure 4, AeF). However, more
importantly, we presented compelling data that the combi-
nation of FOXM1/proteasome inhibitors and ROS inducers
suppresses tumor growth in a human breast cancer xenograft
model (Figure 6, A, C, and D).
We have used RNAi-mediated knockdown of FOXM1 as
a proof of principal to support the assumption that FOXM1
suppression in combination with ROS inducers would further
sensitize cancer cells to cell death (Figure 1A). However, RNAi
treatment in patients is not a plausible therapeutic approach
at present. To circumvent this problem, we tested proteasome
inhibitors that target FOXM121 in combination with ROS
inducers. Proteasome inhibitors were found to be as efﬁcient
(Figure 4, BeF) in regard to induction of cell death as RNAi
(Figure 2, CeI) with the combination of ROS inducers. More
importantly, the combinatorial treatment of proteasome inhibi-
tors and ROS inducers greatly inhibited tumor growth in vivo in
nude mice (Figure 6, A, C, and D). Because proteasome
inhibitor bortezomib is already in clinical practice and the ROS
inducer PEITC is in clinical trials, our data highly support
a feasible treatment strategy for clinical trials based on the
induction of ROS and inhibition of FOXM1 in patients with
tumors already exhibiting high levels of ROS. This novel
combinatorial treatment is projected to be less toxic to
normal cells and highly speciﬁc toward cancer cells
(Figure 4A) because normal cells generally express very
low level of FOXM1 and do not depend on their anti-
oxidant system as much as tumor cells.
Overall, we have proposed and tested the combination of
FOXM1 suppression with ROS induction in preclinical
settings, which has never been tested. Our ﬁndings imply that
targeting FOXM1 in combination with ROS inducers could
offer an effective and applicable treatment strategy against
different types of human cancer with high levels of ROS. We
believe that this combinatorial treatment should be seriously
considered as a feasible anticancer therapy to improve thera-
peutic response in the treatment of cancer.
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